EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Progressive myoclonic ataxia as an initial symptom of typical type I sialidosis with NEU1 mutation

Jingjing Lin, Yun-Lu Li, Bo-Li Chen, Hui-Zhen Su, Yi-Heng Zeng, Rui-Huang Zeng, Yu-Duo Zhang, Ru-Kai Chen iD, Nai-Qing Cai iD, Yi-Kun Chen, Ru-Ying Yuan, Jun-Yi Jiang und 4 weitere

Annals of Clinical and Translational Neurology · 2024

DOI: 10.1002/acn3.52212 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, 2024. Verfasst von Jingjing Lin und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and Institute of Neurology of First Affiliated Hospital, Institute of Neuroscience, and Fujian Key Laboratory of Molecular Ne…. Hauptthemen laut MEDLINE: Mucolipidoses, Neuraminidase, Mutation. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Local Science and Technology Development Project, National Natural Science Foundation of China, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Expand genetic screening for atypical Type I sialidosis (ST‐1) could address its underdiagnosed in both progressive myoclonic ataxia (PMA) and ataxia patients. To evaluate the potential founder effect of mutation in the population.

Methods

We enrolled 231 patients with PMA or ataxia from the First Affiliated Hospital of Fujian Medical University. Through Whole Exome Sequencing and Sanger sequencing, we identified the causative gene in patients. Haplotype analysis was employed to explore a potential founder effect of the NEU1 c.544A>G mutation.

Results

A total of 31 patients from 23 unrelated families were genetically diagnosed with ST‐1. A significant 80.6% of these patients were homozygous for the c.544A>G mutation. We discovered six different NEU1 variants, including two novel mutations: c.951_968del and c.517T>G. The mean age of onset was 18.0 ± 7.1 years. The clinical spectrum of ST‐1 featured ataxia and myoclonus as the most common initial symptoms. Over 40% suffered from controlled generalized tonic–clonic seizures. Mobility and independence varied greatly across the cohort. Cherry‐red spots were rare, occurring in just 9.5% (2/21) of patients. Brain MRIs were typically unremarkable, except for two patients with unusual findings. EEGs showed diffuse paroxysmal activity in 17 patients. The c.544A>G mutation in NEU1 is a founder variant in Fujian, with a unique haplotype prevalent in East Asians.

Interpretation

ST‐1 should be suspected in patients with PMA or ataxia in Southeast China, even without macular cherry‐red spots and seizures, and the premier test could be a variant screening of the founder variant NEU1 c.544A>G.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MucolipidosesNeuraminidaseMutationHumansMaleFemaleAdultAdolescentYoung AdultAtaxiaChildFounder EffectMiddle Aged

Substanzen

NEU1 protein, humanNeuraminidase

Autor:innen und Institutionen

  • Department of Neurology and Institute of Neurology of First Affiliated Hospital, Institute of Neuroscience, and Fujian Key Laboratory of Molecular Neurology, Fujian Medical University, Fuzhou, 350005, China.

ORCID-Profile: Ru-Kai Chen, Nai-Qing Cai, Ning Wang, Wan-Jin Chen, Kang Yang

Förderung

  • Local Science and Technology Development Project
  • National Natural Science Foundation of China
  • National Key Research and Development Program of China
  • Fujian Medical University Affiliated First Hospital Talent Recruitment Research Initiation
  • Natural Science Foundation of Fujian Province
  • Joint Funds for the Innovation of Science and Technology of Fujian Province
  • Fujian Provincial Health Technology projects
  • Major Scientific Research Program for Middle-aged and Young Scientists of Fujian Province

Zitieren

APA

Lin, J., Li, Y. L., Chen, B. L., Su, H. Z., Zeng, Y. H., Zeng, R. H., Zhang, Y. D., Chen, R. K., Cai, N. Q., Chen, Y. K., Yuan, R. Y., Jiang, J. Y., Yao, X. P., Wang, N., Chen, W. J., & Yang, K. (2024). Progressive myoclonic ataxia as an initial symptom of typical type I sialidosis with NEU1 mutation. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.52212

Vancouver

Lin J, Li YL, Chen BL, Su HZ, Zeng YH, Zeng RH, et al. Progressive myoclonic ataxia as an initial symptom of typical type I sialidosis with NEU1 mutation. Annals of Clinical and Translational Neurology. 2024. doi:10.1002/acn3.52212

BibTeX
@article{Lin2024,
  author = {Lin, Jingjing and Li, Yun-Lu and Chen, Bo-Li and Su, Hui-Zhen and Zeng, Yi-Heng and Zeng, Rui-Huang and Zhang, Yu-Duo and Chen, Ru-Kai and Cai, Nai-Qing and Chen, Yi-Kun and Yuan, Ru-Ying and Jiang, Jun-Yi and Yao, Xiang-Ping and Wang, Ning and Chen, Wan-Jin and Yang, Kang},
  title = {Progressive myoclonic ataxia as an initial symptom of typical type I sialidosis with NEU1 mutation},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2024},
  doi = {10.1002/acn3.52212}
}
Kostenlos starten →